Blackrock Neurotech designs and manufactures next‑generation brain‑computer interface (BCI) systems that restore movement, communication, and sensation to patients with neurological disorders such as ALS, Parkinson’s, epilepsy, and paralysis. Leveraging a multidisciplinary team of engineers, neuroscientists, and clinicians, the company has delivered the most mature and clinically validated BCI platform in the world, with more than 30,000 patient‑days of proven benefit and support from over 500 institutional partners. Its flagship MoveAgain system received FDA Breakthrough Device designation in 2021 and is slated for commercial launch in 2023. By integrating advanced neural recordings, real‑time signal processing, and adaptive algorithms, Blackrock Neurotech offers highly customizable solutions that enable patients to regain independence and improve quality of life.
Our Mission: Blackrock Neurotech is 100% focused on improving human lives through neuroscience research and technology. We operate in an innovative field that requires our staff to meet the highest standards. We encourage one another by providing continuous motivation and promoting a healthy work environment. Community Contributions: We also value community education and volunteering in the local community. Disclosure: All offers of employment at Blackrock Neurotech are contingent upon a thorough background check. About the Role: The Senior Electrode R&D Engineer BCI will enable the BCI Electrode team in the design, fabrication, and process characterization and optimization of different neural electrode products.
Blackrock Neurotech designs and manufactures next‑generation brain‑computer interface (BCI) systems that restore movement, communication, and sensation to patients with neurological disorders such as ALS, Parkinson’s, epilepsy, and paralysis. Leveraging a multidisciplinary team of engineers, neuroscientists, and clinicians, the company has delivered the most mature and clinically validated BCI platform in the world, with more than 30,000 patient‑days of proven benefit and support from over 500 institutional partners. Its flagship MoveAgain system received FDA Breakthrough Device designation in 2021 and is slated for commercial launch in 2023. By integrating advanced neural recordings, real‑time signal processing, and adaptive algorithms, Blackrock Neurotech offers highly customizable solutions that enable patients to regain independence and improve quality of life.
Neurosoft Bioelectronics